TGFB1 and neoplasm: As is known, Tregs mediate tumor resistance against ICB in multiple ways, including upregulating the expression of other immune checkpoints including LAG-3, TIM-3, GITR, TIGIT, and VISTA; secreting high levels of TGF-β; and increasing the activation of the PI3K signaling pathway (238, 239).